Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Negoro

Showing results (161-170 of 200) with videos related to

Pageof 20
Sort By:
Journal of the National Cancer Institute|August 21, 1991
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancerS Negoro, M Fukuoka, N Masuda, et al.
British Journal of Cancer|August 15, 2002
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancerM Yamada, S Kudoh, H Fukuda, et al.
Japanese Journal of Cancer Research : Gann|February 1, 1993
Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenograftsS Kudoh, M Takada, N Masuda, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1987
[Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity]K Kitajima, M Fukuoka, S Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1992
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancerN Masuda, M Fukuoka, M Takada, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 1, 1995
[A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group]K Furuse, S Yamori, S Negoro, et al.
Japanese Journal of Cancer Research : Gann|April 1, 1995
Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatinS Kudoh, M Fukuoka, N Masuda, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 10, 2007
Interaction between activated VD3 and Ca channel blockers in patients undergoing hemodialysisS Negoro, S Izumi, T Furukubo, et al.
Journal of the National Cancer Institute|December 4, 1991
Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancerN Masuda, M Fukuoka, K Matsui, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2006
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanY Ohe, Y Ohashi, K Kubota, et al.
Pageof 20

Showing results (161-170 of 200) with videos related to

Sort By:
Pageof 20
Journal of the National Cancer Institute|August 21, 1991
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancerS Negoro, M Fukuoka, N Masuda, et al.
British Journal of Cancer|August 15, 2002
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancerM Yamada, S Kudoh, H Fukuda, et al.
Japanese Journal of Cancer Research : Gann|February 1, 1993
Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenograftsS Kudoh, M Takada, N Masuda, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1987
[Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity]K Kitajima, M Fukuoka, S Kobayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1992
CPT-11 in combination with cisplatin for advanced non-small-cell lung cancerN Masuda, M Fukuoka, M Takada, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 1, 1995
[A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group]K Furuse, S Yamori, S Negoro, et al.
Japanese Journal of Cancer Research : Gann|April 1, 1995
Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatinS Kudoh, M Fukuoka, N Masuda, et al.
International Journal of Clinical Pharmacology and Therapeutics|April 10, 2007
Interaction between activated VD3 and Ca channel blockers in patients undergoing hemodialysisS Negoro, S Izumi, T Furukubo, et al.
Journal of the National Cancer Institute|December 4, 1991
Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancerN Masuda, M Fukuoka, K Matsui, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2006
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanY Ohe, Y Ohashi, K Kubota, et al.
Pageof 20